Efficacy and safety of intracoronary prourokinase during percutaneous coronary intervention in treating ST-segment elevation myocardial infarction patients: a randomized, controlled study

Table 3 Angiographic outcomes, myocardial infarct size and myocardial reperfusion post PCI

Parameters	Intracoronary prourokinase group (N = 25)	Control group (N = 25)	P value
TIMI grade, No. (%)			0.440
0	0 (0.0)	0 (0.0)
1	0 (0.0)	0 (0.0)
2	3 (12.0)	5 (20.0)
3	22 (88.0)	20 (80.0)
TMPG, No. (%)			0.024
0	0 (0.0)	0 (0.0)
1	0 (0.0)	1 (4.0)
2	4 (16.0)	14 (56.0)
3	21 (84.0)	10 (40.0)
CTFC, mean ± SD, frames	16.68 ± 7.26	19.05 ± 6.69	0.235
CK peak value, mean ± SD, U/L	1159.12 ± 617.89	1661.18 ± 1079.60	0.028
CK-MB peak value, mean ± SD, U/L	123.10 ± 31.09	181.56 ± 112.85	0.016
cTnI peak value, mean ± SD, ng/L	38.83 ± 12.53	51.71 ± 26.32	0.032
Complete STR, No. (%)	24 (96.0)	16 (64.0)	0.005

Differences between two groups were determined by Student’s t-test, Mann-Whitney U test, Chi-squared test or Fisher’s exact test, as appropriate. TIMI thrombolysis in myocardial infarction, TMPG TIMI myocardial perfusion grade, CTFC corrected TIMI frame count, SD standard deviation, CK creatine kinase, CK-MB creatine kinase isoenzyme-MB, STR ST segment resolution

ISSN: 1471-2261